The four pillars of our Commitment
Respecting and understanding the patient community perspective
Expanding access to our medicines
Conducting responsible clinical trials
Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Our significant investment in research and development underpins our commitment to using science-based innovation to address some of society's most challenging healthcare issues. Only by working together and delivering on the four pillars of our Commitment to Patients and Caregivers, can we improve outcomes for patients and change the practice of medicine.
40+
Patient organizations representing
200m
Patients contributed to its development
105 533
Novartis associates own it as an aspiration
The Novartis Commitment to Patients and Caregivers
We recognize the importance of patients and caregivers understanding what they can expect from Novartis.
Disclosure of patient organization funding
Novartis annually discloses monetary and non-monetary support to patient organizations around the globe by June 30.
Our Commitment – reporting 2022 progress
87%
Early research programs
in general medicines obtained patient insights before first-in-human trials (healthy volunteers).
7 302
Patients reached through managed access programs
94% requests approved for 55 compounds in 80 countries - providing access to locally unlicensed Novartis medicines. At the end of 2022, more than 9 700 patients were receiving treatment through MAPs.
74
Clinical development programs
comprising 85 clinical trials, had a patient engagement component to obtain the patient perspective on the design and/or conduct of clinical trials.
202
Clinical trials
included Patient Reported Outcomes (PRO) conducted in 77 countries.
191
Simplified summaries
from Phase 1-4 clinical trials sent to investigators to share with 35 500 trial participants and posted on novartis.com/clinicaltrials.
54.2m
Patients
reached through access programs.
Clinical Trials
Managed Access programs
Novartis Managed Access makes investigational or unapproved treatments available to eligible patients with serious or life-threatening diseases. Your physician may request access.
Diversity
Diversity in clinical trials is integral to who we are at Novartis and we are working hard to improve both the diversity of patients enrolled in our clinical research and the investigators involved in our trials. (PDF 0.2 MB)
Collaborations with Patient Organizations
Sound up for lung cancer research
Global Oncology Patient Insights Panels (GOPIPs) are giving patients and advocates a critical voice in advancing lung cancer trials.
Patient Organizations and Novartis
We collaborate with patient organizations and healthcare organizations globally in the disease areas for which we provide or are developing medicines. This collaboration is based on values of mutual respect, trust and transparency.
External Funding
Novartis may provide funding to legitimate organizations to support its mission to discover new ways to improve and extend people's lives, advancing scientific and medical knowledge, and supporting the communities where Novartis Associates live and work.
Patient Perspectives
We commit to actively seeking out and listening to insights from the patient community. Visit our YouTube channel to watch our Patient & Caregiver stories and learn more about our resources.
For questions about Novartis, medical inquiries about our products and/or information about services, we recommend you contact the Novartis office in your country. If you’re seeking a global list of products, visit our Global Product Portfolio.